Man & Science Expands its Headache Disorder Treatment Portfolio with Acquisition of Palion Medical

"The acquisition of Palion Medical fits well into our leading headache treatment offerings and further drives Man & Science's ability to provide several therapy solutions to improve patient care," said Robert Taub, Chairman and architect of this business combination. "Palion Medical's technology is very ...

‍

Discover more news

January 30, 2023

Man & Science Closes €7.4 Million in Capital Increase

September 5, 2022

Man & Science announces U.S. FDA Breakthrough Device Designation Granted for the treatment of Chronic Cluster Headache

Man & Science announced today that it has been granted a Breakthrough Device Designation by the Center of Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for its minimally invasive innovative neuromodulation therapy for the treatment of Chronic Cluster Headache (CCH).

Man & Science Expands its Headache Disorder Treatment Portfolio with Acquisition of Palion Medical

Discover more news

Man & Science Closes €7.4 Million in Capital Increase

Man & Science announces U.S. FDA Breakthrough Device Designation Granted for the treatment of Chronic Cluster Headache

Contact